Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
<b><i>Introduction:</i></b> Oral antifungals were the earliest treatments to receive approval for the management of onychomycosis and have a long-standing record to support their efficacy. Topical antifungals and device-based treatments have been explored and some implemented in more recent years as alternatives to traditional oral antifungals. The present bibliometric analysis summarizes trends in publication frequency for onychomycosis treatment modalities over time and characterizes their body of literature in terms of types of studies available and relative level of evidence. <b><i>Methods:</i></b> A comprehensive literature search was performed using Web of Science and SCOPUS databases. <b><i>Results:</i></b> Covering all publications from 1970 to present day, our search identified oral therapeutics <i>n</i> = 295 articles (<i>n</i> = 63 randomized control trials [RCTs]), topical therapeutics <i>n</i> = 358 articles (<i>n</i> = 72 RCTs), and device-based treatments <i>n</i> = 158 articles (<i>n</i> = 37 RCTs). Spikes in research activity surround FDA approval of therapeutics for each treatment modality. Research activity within the last decade has focused on topical and device-based treatments. Evidence for efficacy of device-based treatments is lacking from relatively few high-quality RCTs. <b><i>Conclusion:</i></b> With growing concern for non-dermatophyte mold onychomycosis and terbinafine resistance, researchers should validate the efficacy and safety of device-based treatments with high-quality studies.
<b><i>Introduction:</i></b> Oral antifungals were the earliest treatments to receive approval for the management of onychomycosis and have a long-standing record to support their efficacy. Topical antifungals and device-based treatments have been explored and some implemented in more recent years as alternatives to traditional oral antifungals. The present bibliometric analysis summarizes trends in publication frequency for onychomycosis treatment modalities over time and characterizes their body of literature in terms of types of studies available and relative level of evidence. <b><i>Methods:</i></b> A comprehensive literature search was performed using Web of Science and SCOPUS databases. <b><i>Results:</i></b> Covering all publications from 1970 to present day, our search identified oral therapeutics <i>n</i> = 295 articles (<i>n</i> = 63 randomized control trials [RCTs]), topical therapeutics <i>n</i> = 358 articles (<i>n</i> = 72 RCTs), and device-based treatments <i>n</i> = 158 articles (<i>n</i> = 37 RCTs). Spikes in research activity surround FDA approval of therapeutics for each treatment modality. Research activity within the last decade has focused on topical and device-based treatments. Evidence for efficacy of device-based treatments is lacking from relatively few high-quality RCTs. <b><i>Conclusion:</i></b> With growing concern for non-dermatophyte mold onychomycosis and terbinafine resistance, researchers should validate the efficacy and safety of device-based treatments with high-quality studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.